It’s not often you get excited talking about company mergers, but a deal announced today is something worth getting excited about, particularly if you have type 1 diabetes (T1D). Today Vertex announced it was buying ViaCyte for $320 million in cash. Why is that important? Because both companies are working on developing stem cell therapies … Continue reading A big deal for type 1 diabetes
Viacyte
First Patient Dosed in Phase 1 Clinical Trial for T1D
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST There’s some good news for a company and a therapeutic approach that CIRM has been supporting for many years. In September 2018, CRISPR Theraputics and ViaCyte entered a partnership to discover, develop and market gene-edited stem cell-derived therapies to treat type 1 diabetes (T1D). Today, they may stand … Continue reading First Patient Dosed in Phase 1 Clinical Trial for T1D
Producing insulin for people who can’t
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST ViaCyte's implantable stem cell pouch One of the huge advantages of a stem cell agency like CIRM (not that there is anything out there quite like us, but anyway) is our ability to support projects as they progress from a great idea to a therapy actually … Continue reading Producing insulin for people who can’t
Type 1 diabetes therapy gets go-ahead for clinical trial
ViaCyte's implantable cell-based therapy for type 1 diabetes THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Taking even the most promising therapy and moving it out of the lab and into people is an incredibly complex process and usually requires a great team. Now, two great teams have paired up to do just that … Continue reading Type 1 diabetes therapy gets go-ahead for clinical trial
Getting under the skin of people with type 1 diabetes – but in a good way
THIS BLOG IS ALSO AVAILABLE AS AN AUDIOCAST As someone with a family history of type 1 diabetes (T1D) I know how devastating the condition can be. I also know how challenging it can be to keep it under control and the consequences of failing to do that. Not maintaining healthy blood sugar levels can … Continue reading Getting under the skin of people with type 1 diabetes – but in a good way
Breakthrough for type 1 diabetes: scientist discovers how to grow insulin-producing cells
Matthias Hebrok, PhD, senior author of new study that transformed human stem cells into mature, insulin-producing cells. Photo courtesy of UCSF. More often than not, people don't really think about their blood sugar levels before sitting down to enjoy a delicious meal, partake in a tasty dessert, or go out for a bicycle ride. But … Continue reading Breakthrough for type 1 diabetes: scientist discovers how to grow insulin-producing cells
CIRM-supported Type I Diabetes treatment enters clinical trials in Europe
ViaCyte, a company that CIRM has supported for many years, has announced international expansion of a clinical trial to test their therapeutic PEC-Direct product in patients with Type I Diabetes. The first European patient in Brussels was implanted with the PEC-Direct product candidate that, in animal models, is able to form functional beta cells. Patients … Continue reading CIRM-supported Type I Diabetes treatment enters clinical trials in Europe
How CIRM support helped a promising approach to type 1 diabetes get vital financial backing
The “Valley of Death” sounds like a scary place from “Lord of the Rings” or “Game of Thrones” that our heroes have to navigate to reach safety. The reality is not that different. It’s the space that young companies have to navigate from having a good idea to getting financial backing, so they can move … Continue reading How CIRM support helped a promising approach to type 1 diabetes get vital financial backing
New partnership to make CIRM supported treatment for type 1 diabetes even better
ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better
CIRM-Funded Research Makes Multiple Headlines this Week
When it rains it pours. This week, multiple CIRM-funded studies appeared in the news, highlighting the exciting progress our Agency is making towards funding innovative stem cell research and promoting the development of promising stem cell therapies for patients. Below are highlights. Fate Therapeutics Partners with UC San Diego to Develop Cancer Immunotherapy Last week, … Continue reading CIRM-Funded Research Makes Multiple Headlines this Week
The Stem Cellar 